Phytogen Life Sciences Inc.
Delta, BC
Company Overview
Phytogen Life Sciences Inc. is in the business of developing, manufacturing, and commercializing pharmaceuticals derived from natural sources. Phytogen is a manufacturer of pharmaceutical grade paclitaxel, a novel anti-tumour agent referred to in some scientific and medical literature as 'taxol.'
Paclitaxel has been shown to be a safe and effective agent in the treatment of advanced ovarian and breast cancer, and in other forms of the disease. The total market for paclitaxel reached US $1.6 billion in 2000, and it use is expected to continue to grow as new indications for the use of Taxol are approved.
In 1994 the company completed construction of a 22, 000 sq. ft. building equipped to produce paclitaxel as a bulk pharmaceutical product to clinical purity standards under cGMP. In 1996 Phytogen filed a Drug Master File with the US Food and Drug Administration in preparation for marketing in the United States. The Companys state-of-the-art production facility in British Columbia is operated in accordance with the US regulatory requirements known as current Good Manufacturing Practices (cGMP). In June 1998, Phytogen completed its US Food and Drug Administration (FDA) and Canadian Health Protection Branch (HPB) pre-approval inspections of its facility and processes with respect to the Companys production of paclitaxel active pharmaceutical ingredient ('API'), Phytogens first commercial product. Both agencies confirmed that the Company is in compliance with cGMP guidelines and both approved Phytogen as a producer of API. Such approval enables the Company to sell its paclitaxel API worldwide.
In April 2000, the Company received a Notice of Allowance from the US Patent and Trademark Office regarding the acceptance of its patent application, covering 61 separate claims on certain aspects of its paclitaxel production processes and product composition. The patent was issued in October, 2000. A PCT has been filed for European patent protection.
A PCT patent for the Preparation of Etoposide was issued in January, 2001.
The company has a mutually exclusive license and supply agreement with Mylan Pharmaceuticals Inc. for generic paclitaxel product in the USA, Canada, and Mexico. Phytogen is presently in seeking pharmaceutical strategic partners for introduction of paclitaxel products in other strategic markets.
Phytogen is also actively involved in sourcing other new drugs for development, for both the anti-cancer and anti- viral markets.
Company Information
Physical Address
1527 Cliveden Ave.
Delta, BC V3M 6P7
CA
Mailing Address
1527 Cliveden Ave.
Delta, BC V3M 6P7
CA
Additional Details
Legal Name: Phytogen Life Sciences Inc.
Number of Employees: 30
CA
Contacts
Fausto Taddei
Title: Vice President
Area of Responsibility: Finance/Accounting
Phone: Show phone
Fax: Show fax
Email: Show email
Diane Wierzbicki
Title: Vice President
Area of Responsibility: Management Executive
Phone: Show phone
Fax: Show fax
Email: Show email
Hy Foo
Title: President
Area of Responsibility: Management Executive
Phone: Show phone
Fax: Show fax
Samuel Foo
Title: Vice President
Area of Responsibility: Research/Development/Engineering
Phone: Show phone
Fax: Show fax
Services
- Biotechnology
Products
-
Etoposide
Etoposide
- Paclitaxel
NAICS Categories
Additional Information
325410
Brazil, United Kingdom